PMID- 25469285
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240322
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 3
IP  - 1
DP  - 2015 Jan
TI  - Indirect comparison of the efficacy and safety of gefitinib and cetuximab-based 
      therapy in patients with advanced non-small-cell lung cancer.
PG  - 145-150
AB  - The aim of this study was to systematically evaluate the efficacy and safety of 
      gefitinib and cetuximab-based therapies in patients with advanced non-small-cell 
      lung cancer (NSCLC). The studies to be used for the comparisons were selected 
      from the available literature on gefitinib and cetuximab-based therapies compared 
      to conventional chemotherapy in patients with advanced NSCLC. The meta-analysis 
      was performed with RevMan 5.0 software and the Bucher approach was applied to 
      conduct the indirect comparisons. A total of 4 studies, including 935 patients, 
      on gefitinib therapy vs. conventional chemotherapy and 4 studies, including 1,015 
      patients, on cetuximab-based therapy vs. conventional chemotherapy, were used for 
      indirect comparisons. As regards efficacy, the risk ratio (RR) of objective 
      response rate and 1-year survival rate between gefitinib and cetuximab-based 
      therapies in patients with advanced NSCLC were 0.99 [95% confidence interval 
      (CI): 0.75-1.32; P=0.9584] and 0.85 (95% CI: 0.71-1.01; P=0.0696), respectively, 
      and the mean difference of progression-free survival and overall survival (OS) 
      were -0.15 (95% CI: -0.90 to 0.60; P=0.6946) and -1.84 (95% CI: -3.53 to -0.15; 
      P=0.0331), respectively. As regards safety, the RR of grade 3/4 adverse events 
      (AEs) was 0.29 (95% CI: 0.19-0.44; P=0.0001). The results demonstrated that 
      cetuximab-based therapy was superior to gefitinib therapy in terms of OS and 
      inferior to gefitinib therapy in terms of AEs, whereas there were no significant 
      differences in terms of efficacy and safety between the two therapies on other 
      endpoints adopted for advanced NSCLC. However, further well-designed randomized 
      controlled trials and continuous studies are required to confirm our findings.
FAU - Tang, Jifeng
AU  - Tang J
AD  - The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical 
      University, Nanjing, Jiangsu 211198, P.R. China ; School of International 
      Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu 
      211198, P.R. China.
FAU - Zhang, Hena
AU  - Zhang H
AD  - The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical 
      University, Nanjing, Jiangsu 211198, P.R. China ; School of International 
      Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu 
      211198, P.R. China.
FAU - Yan, Jianzhou
AU  - Yan J
AD  - The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical 
      University, Nanjing, Jiangsu 211198, P.R. China ; The Research Center of National 
      Drug Policy and Ecosystem, China Pharmaceutical University, Nanjing, Jiangsu 
      211198, P.R. China.
FAU - Shao, Rong
AU  - Shao R
AD  - The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical 
      University, Nanjing, Jiangsu 211198, P.R. China ; The Research Center of National 
      Drug Policy and Ecosystem, China Pharmaceutical University, Nanjing, Jiangsu 
      211198, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20140922
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC4251263
OTO - NOTNLM
OT  - cetuximab
OT  - chemotherapy
OT  - gefitinib
OT  - indirect comparison
OT  - meta-analysis
OT  - non-small-cell lung cancer
EDAT- 2014/12/04 06:00
MHDA- 2014/12/04 06:01
PMCR- 2014/09/22
CRDT- 2014/12/04 06:00
PHST- 2013/11/13 00:00 [received]
PHST- 2014/09/09 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2014/12/04 06:01 [medline]
PHST- 2014/09/22 00:00 [pmc-release]
AID - mco-03-01-0145 [pii]
AID - 10.3892/mco.2014.424 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2015 Jan;3(1):145-150. doi: 10.3892/mco.2014.424. Epub 2014 Sep 
      22.